Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody – Bevacizumab – and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies

FORMICA, MARÍA LINA; LEGEAY, SAMUEL; BEJAUD, JÉRÔME; MONTICH, GUILLERMO GABRIEL; ULLIO GAMBOA, GABRIELA VERÓNICA; BENOIT, JEAN-PIERRE; PALMA, SANTIAGO DANIEL

MATERIALS SCIENCE & ENGINEERING. C, BIOMIMETIC MATERIALS, SENSORS AND SYSTEMS

ELSEVIER SCIENCE BV

Año: 2021 vol. 119

0928-4931

The aim of this study was to design and develop a novel hybrid formulation based on lipid nanocapsules containing bevacizumab (BVZ), an effective therapeutic antibody, on the surface and triamcinolone acetonide (TA) in the inner core (BVZ-TA-LNC) intended to improve ocular therapy. Hence, a phase inversion-insertion one step method was developed to drug loading and surface modification of lipid nanocapsules by post-insertion of a bifunctional polymer, followed by antibody coupling using ?click? chemistry. The covalent bond and antibody capacity binding to its specific antigen were confirmed by thermal analysis and immunoassay, respectively. BVZ-TA-LNC presented nanometric size (102 nm), negative surface potential (−19 mV) and exhibiting 56% of TA in the lipid core. BVZ-TA-LNC tended to prevent the endothelial cell migration and significantly prevented the capillary formation induced by the vascular endothelium growth factor (VEGF). The novel hybrid system allowed the co-loading of two different therapeutic molecules and may be promising to improve the therapy of eye disorders that occur with inflammation and/or neovascularization.